Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Ardelyx to present hyperphosphatemia research at ASN meeting

Ardelyx to present hyperphosphatemia research at ASN meeting

Ardelyx Inc., a commercial-stage biopharmaceutical company, will showcase three abstracts at the American Society of Nephrology Kidney Week 2026, set to take place from October 21-25 in Denver, Colorado. These posters will delve into hyperphosphatemia research, focusing on real-world efficacy of tenapanor with various phosphate binders, patient experiences managing hyperphosphatemia, and the long-term effects on dialysis patients' health.

The presentations are scheduled for October 23, spanning from 10:00 am to 12:00 pm MDT. The first poster will explore the real-world impact of tenapanor and serum phosphate outcomes based on existing phosphate binder usage. The second poster will share insights from an online survey on patients' perspectives regarding hyperphosphatemia management in end-stage kidney disease cases.

Lastly, the third poster will analyze the morbidity and mortality risks linked to persistent hyperphosphatemia in U.S. dialysis patients. In addition to the poster presentations, Ardelyx will host an exhibitor session on October 23 at 11:00 am MDT, titled "Expanding Perspectives in Hyperphosphatemia Treatment: A Different Approach."

This session will feature Nephrologist Samuel A. Kantor delivering a talk on XPHOZAH, the company's FDA-approved drug for reducing serum phosphorus in chronic kidney disease patients on dialysis. XPHOZAH, which extends beyond phosphate binder therapy or intolerance to it, shows promise but is not without side effects, the most common being diarrhea, reported in 43-53% of clinical trial participants.

Ardelyx's portfolio also includes IBSRELA, another tenapanor-based product, both contributing significantly to the company's growth.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Health & Medicine

More from Monday 5 October →